Search
Bordetella pertussis pertactin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10992ApprovedInvestigationalMixtures: Repevax Injektionssuspension in einer FertigspritzeIbrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.
Synonyms: enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor, (1S,4AR,6AS,7R,8R,10AR,10BR,12AR,14R,15R)-15-((2R)- 2-AMINO-2,3,3-TRIMETHYLBUTOXY)-1,6A,8,10A-TETRAMETHYL-8- ((2R)-3-METHYLBUTAN-2-YL)-14-(5-(PYRIDIN-4-YL)-1H-1,2,4- TRIAZOL-1-YL)-1,6,6A,7,8,9,10,10A,10BCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.
Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-AminopyridineBempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … [A247050] The use of oteseconazole is contraindicated in females of reproductive potential due to its embryo-fetal toxicity risks.[L41635] This drug was approved by the FDA on April 26, 2022.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol, 2-Pyridineethanol, α-(2,4difluorophenyl)-β β-difluoro- α-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-,(αR)Pyrimidine Metabolism
smpdb.ca/view/SMP0000046MetabolicPyrimidine catabolism ultimately results in the formation of the waste products of urea, H2O, and CO2. … A group of heterocyclic aromatic organic compound, pyrimidines are similar in structure to benzene and pyridine and count the nucleic acids cytosine, thymine, and uracil as structural derivatives.
beta-Ureidopropionase Deficiency
smpdb.ca/view/SMP0000172DiseaseA deficiency in this enzyme results in accumulation of N-carbamyl-beta-amino acids. Symptoms include hypotonia, dystonic movements, scoliosis, microcephaly, and severe developmental delay. … Beta-ureidopropionase deficiency (Beta Alanine-Synthase Deficiency, UPB1, BUP1) is an autosomal recessive disease caused by mutations in the UPB1 gene which codes for beta-ureidopropionase.
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)
smpdb.ca/view/SMP0000202DiseaseMNGIE causes accumulation of thymidine and deoxyuridine in the urine. … Myoneurogastrointestinal encephalopathy, or mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), is a multisystem disorder caused by mutations in the gene encoding thymidine phosphorylase
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)
smpdb.ca/view/SMP0125720DiseaseMNGIE causes accumulation of thymidine and deoxyuridine in the urine. … Myoneurogastrointestinal encephalopathy, or mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), is a multisystem disorder caused by mutations in the gene encoding thymidine phosphorylase
UMP Synthase Deficiency (Orotic Aciduria)
smpdb.ca/view/SMP0000219DiseaseThis disease is characterized by a very large accumulation of orotic acid in the urine, occasionally causing urinary obstruction.